-

Media Alert for Durnell Supreme Court Argument

LEVERKUSEN, Germany & ST. LOUIS--(BUSINESS WIRE)--On April 27th, Monsanto will argue before the U.S. Supreme Court in Durnell v. Monsanto, a Roundup case involving the application of federal preemption under FIFRA. A favorable ruling by the Supreme Court would provide essential regulatory clarity for companies who seek to bring currently approved and new products to market, addressing their ability to serve U.S. farmers and consumers. Former Solicitor General Paul Clement will argue the case for Monsanto.

More than 100 government, farm, business and non-profit groups – including the U.S. government --joined amici briefs in support of Monsanto’s position, urging the nation’s highest court to affirm Congress’ intent in including a “Uniformity” provision in FIFRA, and prevent a patchwork of state laws and labelling requirements which would threaten businesses, the economy, and farmers. Read more about the amici support for Monsanto here.

Monsanto also released the following statement regarding the oral argument in Durnell:

“Congress enacted FIFRA to establish a uniform, nationwide framework governing pesticide registration and labeling, and companies should not face liability under state law for complying with federally approved and science-based labeling requirements. Allowing such claims to proceed invites a patchwork of state standards that conflict with the uniformity objective Congress prescribed in law and creates regulatory uncertainties that impede the development of new agricultural innovations. The security and affordability of the nation’s food supply depend on farmers’ and manufacturers’ ability to rely on the science-based judgments of federal regulators. Clarification from the Court is essential to restore uniformity, certainty, and the rule of law.”

Contacts

Media Contact:
Brian Leake
(314) 370.3285

Monsanto


Release Versions

Contacts

Media Contact:
Brian Leake
(314) 370.3285

More News From Monsanto

Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential

BERLIN--(BUSINESS WIRE)--Bayer today announced a leadership change within its Pharmaceuticals’ Worldwide Markets organization to accelerate the strong performance and growth of its key pharmaceutical products in the U.S. Effective May 1, 2026, Nelson Ambrogio, currently President of Bayer’s global Radiology business, will be appointed President of Bayer U.S. Pharmaceuticals. Nelson Ambrogio will guide the U.S. Pharmaceuticals organization into its next chapter of growth and build on the strong...

Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris

WHIPPANY, N.J.--(BUSINESS WIRE)--One A Day®, the multivitamin and supplement brand from Bayer backed by more than 80 years of nutritional science, today announced a partnership with Grammy Award winning recording artist, actor and philanthropist Ludacris. The collaboration brings together two names with a shared commitment to simplicity, consistency, and staying power—demonstrating how effortlessly consumers can support their health in a straightforward way with One A Day®. What is the new camp...

KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

WHIPPANY, N.J.--(BUSINESS WIRE)--The Phase III study FIND-CKD (NCT05047263) — investigating the efficacy and safety of KERENDIA® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD) — has met its primary endpoint.1 The results demonstrated a statistically significant improvement versus placebo in the primary efficacy outcome of estimated glomerular filtration rate (eGFR) slope, defined as the mean annual rate of change from...
Back to Newsroom